INVIVYD INC. - COMMON STOCK

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

08 Jan 2026 07:01:00 By Nasdaq GlobeNewswire

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

23 Dec 2025 07:05:00 By Nasdaq GlobeNewswire

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

23 Dec 2025 07:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

25 Nov 2025 07:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

24 Nov 2025 07:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

17 Nov 2025 22:40:00 By Nasdaq GlobeNewswire

Invivyd Announces Proposed Public Offering of Common Stock

17 Nov 2025 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

06 Nov 2025 07:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

03 Nov 2025 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

28 Oct 2025 07:01:00 By Nasdaq GlobeNewswire

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

06 Oct 2025 07:01:00 By Nasdaq GlobeNewswire

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

24 Sep 2025 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

17 Sep 2025 07:01:20 By Nasdaq GlobeNewswire

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

04 Sep 2025 07:10:54 By Nasdaq GlobeNewswire

Invivyd to Participate in Upcoming Investor Conferences

27 Aug 2025 07:01:33 By Nasdaq GlobeNewswire

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares

22 Aug 2025 12:00:47 By Nasdaq GlobeNewswire

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

20 Aug 2025 23:58:25 By Nasdaq GlobeNewswire

Invivyd Announces Proposed Public Offering of Common Stock

20 Aug 2025 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

18 Aug 2025 16:32:40 By Nasdaq GlobeNewswire

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

14 Aug 2025 16:49:30 By Nasdaq GlobeNewswire